<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id><journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id><journal-id journal-id-type="publisher-id">MEDI</journal-id><journal-title-group><journal-title>Medicine</journal-title></journal-title-group><issn pub-type="ppub">0025-7974</issn><issn pub-type="epub">1536-5964</issn><publisher><publisher-name>Wolters Kluwer Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28514309</article-id><article-id pub-id-type="pmc">5440146</article-id><article-id pub-id-type="publisher-id">MD-D-17-01410</article-id><article-id pub-id-type="doi">10.1097/MD.0000000000006919</article-id><article-id pub-id-type="art-access-id">06919</article-id><article-categories><subj-group subj-group-type="heading"><subject>5300</subject></subj-group><subj-group><subject>Research Article</subject><subject>Clinical Trial/Experimental Study</subject></subj-group></article-categories><title-group><article-title>A randomized controlled trial of botulinum toxin A for treating neuropathic pain in patients with spinal cord injury</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Li</surname><given-names>Gang</given-names></name><degrees>MB</degrees><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lv</surname><given-names>Chang-an</given-names></name><degrees>MB</degrees><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tian</surname><given-names>Li</given-names></name><degrees>MB</degrees><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Jin</surname><given-names>Lian-jin</given-names></name><degrees>MM</degrees><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Ping</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Wei</given-names></name><degrees>MM</degrees><xref ref-type="aff" rid="aff4"><sup>d</sup></xref><xref rid="cor1" ref-type="corresp"><sup>&#x02217;</sup></xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Martin.</surname><given-names>Samantha</given-names></name></contrib></contrib-group><aff id="aff1"><label>a</label>Department of Orthopedic Surgery</aff><aff id="aff2"><label>b</label>Department of Critical-care Medicine</aff><aff id="aff3"><label>c</label>Department of Anesthesia, The Affiliated Hongqi Hospital, Mudanjiang Medical University</aff><aff id="aff4"><label>d</label>Department of Anatomy, Mudanjiang Medical University, Mudanjiang, China.</aff><author-notes id="cor1"><corresp><label>&#x02217;</label>Correspondence: Wei Zhao, Department of Anatomy, Mudanjiang Medical University, No. 3 Tongxiang Road, Aiming District, Mudanjiang 157011, China (e-mail: <email>522872643@qq.com</email>).</corresp></author-notes><pub-date pub-type="collection"><month>5</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>19</day><month>5</month><year>2017</year></pub-date><volume>96</volume><issue>20</issue><elocation-id>e6919</elocation-id><history><date date-type="received"><day>7</day><month>3</month><year>2017</year></date><date date-type="rev-recd"><day>17</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>25</day><month>4</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2017 the Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0">http://creativecommons.org/licenses/by-nc-nd/4.0</ext-link></license-p></license></permissions><self-uri xlink:type="simple" xlink:href="medi-96-e6919.pdf"/><abstract><title>Abstract</title><sec sec-type="background"><title>Background:</title><p>To assess the effect of botulinum toxin A (BTA) for treating neuropathic pain in patients with spinal cord injury (SCI).</p></sec><sec sec-type="methods"><title>Methods:</title><p>A total of 44 patients with SCI with neuropathic pain were randomly divided into the intervention group and the placebo group, each group 21 patients. The subjects in the intervention group received BTA (200 U subcutaneous injection, once daily) at the painful area, whereas those in the placebo group were administered a saline placebo. This study was conducted from December 2014 to November 2016. The primary outcome was measured using the visual analog scale (VAS). The secondary outcomes were measured using the short-form McGill Pain Questionnaire (SF-MPQ), and World Health Organization quality of life (WHOQOL-BREF) questionnaire. All outcome measurements were performed before and after 4 and 8 weeks of intervention.</p></sec><sec sec-type="results"><title>Results:</title><p>Forty-one participants completed the study. The intervention with BTA showed greater efficacy than placebo in decreasing the VAS score after week 4 and week 8 of treatment. Significant differences in the SF-MPQ and WHOQOL-BREF were also found between the 2 groups.</p></sec><sec sec-type="conclusion"><title>Conclusion:</title><p>The results of this study demonstrated that BTA might decrease intractable neuropathic pain for patients with SCI.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>botulinum toxin A</kwd><kwd>clinical trial</kwd><kwd>neuropathic pain</kwd><kwd>spinal cord injury</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec><label>1</label><title>Introduction</title><p>Neuropathic pain is defined as &#x0201c;pain caused by a lesion or disease of the somatosensory system.&#x0201d;<sup>[<xref rid="R1" ref-type="bibr">1</xref>&#x02013;<xref rid="R7" ref-type="bibr">7</xref>]</sup> It is one of the most common complications of spinal cord injury (SCI), with prevalence ranging between 75% and 81%.<sup>[<xref rid="R8" ref-type="bibr">8</xref>&#x02013;<xref rid="R13" ref-type="bibr">13</xref>]</sup> This type of pain often leads to poor quality of life and interferes with cognitive, emotional, and physical functioning following SCI.<sup>[<xref rid="R14" ref-type="bibr">14</xref>]</sup> Moreover, the pain is usually severe, refractory to treatment, and persistent for a long time.<sup>[<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R15" ref-type="bibr">15</xref>&#x02013;<xref rid="R17" ref-type="bibr">17</xref>]</sup></p><p>Botulinum toxin type A (BTA) is a potent neurotoxin and is usually used for treating focal muscle dystonia and spasticity.<sup>[<xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref>]</sup> Previous studies have reported that BTA had promising effect for treating chronic neuropathic pain syndromes associated with muscle disorders.<sup>[<xref rid="R20" ref-type="bibr">20</xref>&#x02013;<xref rid="R22" ref-type="bibr">22</xref>]</sup> Its mechanism involves the preventing neurogenic inflammation and also reducing the peripheral sensitization of nociceptive fibers.<sup>[<xref rid="R23" ref-type="bibr">23</xref>&#x02013;<xref rid="R25" ref-type="bibr">25</xref>]</sup> Moreover, its central mechanism involves the antinociceptive effect by the axonal transport on the spinal cord.<sup>[<xref rid="R26" ref-type="bibr">26</xref>,<xref rid="R27" ref-type="bibr">27</xref>]</sup></p><p>In this study, we tested the hypothesis that BTA could reduce neuropathic pain in patients with SCI.</p></sec><sec><label>2</label><title>Methods</title><sec><label>2.1</label><title>Design</title><p>This study was designed as a randomized double-blind placebo-controlled trial. This study was approved by the Medical Ethical Committee of Hongqi Hospital of Mudanjiang Medical School and was conducted at this hospital. Forty-four SCI patients with neuropathic pain were recruited in this study from December 2014 to November 2016. All patients were identified and selected based on the inclusion and exclusion criteria. All included subjects were randomly divided into the intervention group or the placebo group in a 1:1 ratio.</p></sec><sec><label>2.2</label><title>Inclusion and exclusion criteria</title><p>The inclusion criteria were patients with SCI with neuropathic pain aged from 18 to 65 years, levels of SCI from A to D (American Spinal Injury Association [ASIA] impairment scale), more than 1 year after SCI, daily neuropathic pain lasting more than 3 months, and visual analog scale (VAS) score &#x02265;40 (VAS, 0&#x02013;100&#x0200a;mm). The subjects were excluded if they had a contraindication, hypersensitivity, history of BTA, any other reasons that led to neuropathic pain except SCI, coagulation disorders, pregnancy, or declined to participate. However, the other concomitant analgesic medication with stable dose was allowed in this study.</p></sec><sec><label>2.3</label><title>Randomization and blinding</title><p>Block randomization schedule was performed using a computerized number generator by SAS Software (version 8.3; SAS Institute Inc, Cary, NC). The randomization assignments were concealed in opaque sequentially numbered sealed envelopes. Then, 44 eligible patients were assigned at a 1:1 ratio to the intervention group or placebo group. The patients, clinicians, outcome assessors, as well as data analysts were blinded to the treatment allocation.</p></sec></sec><sec><label>3</label><title>Intervention</title><p>All participants were administered a subcutaneous injection of 200 U BTA (Research Biological Institute of Lanzhou HengLi Botox, Lanzhou, Gansu, China) in 4&#x0200a;mL saline solution at the painful area in the intervention group. Patients in the placebo group received 4&#x0200a;mL saline solution at the painful area. Subjects in both groups were treated once daily for 8 weeks.</p><sec><label>3.1</label><title>Outcome measurements</title><p>The primary outcome was measured using VAS scale (0&#x0200a;=&#x0200a;no pain, 100&#x0200a;=&#x0200a;worst pain imaginable). The secondary outcome measurements consisted of the short-form McGill Pain Questionnaire (SF-MPQ) and World Health Organization quality of life (WHOQOL-BREF) questionnaire.<sup>[<xref rid="R28" ref-type="bibr">28</xref>]</sup> All the primary and secondary outcomes were measured and evaluated after 4 weeks and 8 weeks of treatment. In addition, all the adverse events (AEs) of BTA were recorded in this study.</p></sec><sec><label>3.2</label><title>Statistical analysis</title><p>The estimated sample size was 22 patients in each group with the VAS of 20&#x0200a;mm, and the difference of standard deviation of 2&#x0200a;mm at week 4 (change from baseline), &#x003b1;&#x0200a;=&#x0200a;0.05 (2-sided) and &#x003b2;&#x0200a;=&#x0200a;0.20.<sup>[<xref rid="R21" ref-type="bibr">21</xref>]</sup> Assuming a 15% dropout rate, at least 44 patients with 22 in each group were required to be recruited in this study. All outcome data were analyzed by an intention-to-treat (ITT) approach. <italic>t</italic> test or Wilcoxon rank sum test was used to analyze the data with relative risks and 95% confidence intervals.</p></sec></sec><sec><label>4</label><title>Results</title><p>Sixty-seven patients initially entered the study (Fig. <xref ref-type="fig" rid="F1">1</xref>). Of these 67, 20 individuals did not meet the inclusion criteria, and 3 declined to participate. Therefore, 44 patients were randomized into the study. All included participants received the study medication and all the data of primary and secondary outcomes were analyzed by an ITT approach. Three patients withdrew from the study. The major reasons for withdrawal were the withdrawal of consent and patients who were lost to follow-up (Fig. <xref ref-type="fig" rid="F1">1</xref>). In addition, the characteristics of all included patients at baseline are shown in Table <xref ref-type="table" rid="T1">1</xref>.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Flow of patients through the trial.</p></caption><graphic xlink:href="medi-96-e6919-g001"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Patients characteristics at baseline.</p></caption><graphic xlink:href="medi-96-e6919-g002"/></table-wrap><p>We examined the mean change from the baseline by intervention and the difference between BTA and placebo groups to evaluate the efficacy of BTA. The results for the efficacy endpoints at the end of week-4 and week-8 are summarized in Table <xref ref-type="table" rid="T2">2</xref>. BTA treatment improved all primary and secondary outcomes compared with placebo at the end of week 4 and week 8. At the end of week 4 of treatment, the BTA group exhibited significant improvements in VAS, SF-MPQ, and WHOQOL-BREF scores compared with the placebo group (Table <xref ref-type="table" rid="T2">2</xref>). These improvements were maintained throughout the end of week 8 (Table <xref ref-type="table" rid="T2">2</xref>).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Outcome measurements at the end of 4-week, and 8-week treatment (change from baseline).</p></caption><graphic xlink:href="medi-96-e6919-g003"/></table-wrap><p>No allergic reactions occurred in both groups. In addition, no other local or systemic side effects were recorded and reported in this study, except 4 patients in the BTA group and 3 participants in the placebo group reported that the injections were painful but with no significant difference. In addition, no treatment-related deaths were found in both groups.</p></sec><sec><label>5</label><title>Discussion</title><p>Neuropathic pain manifests as burning, electric, or shooting with accompanying sensory changes of allodynia or hyperalgesia. It often consists of 2 subtypes with at-level and below-level neuropathic pain according to the pain pathology. The first involves a segmental pattern and occurs at the associated level of neurological injury or within 3 dermatomes below this level.<sup>[<xref rid="R29" ref-type="bibr">29</xref>]</sup> The latter subtype occurs more than 3 dermatomes below the neurological level of injury and is commonly associated with spinal cord trauma and ischemia.<sup>[<xref rid="R30" ref-type="bibr">30</xref>]</sup> In this study, BTA injection was used to treat below-level neuropathic pain after SCI according to the pathological differences underlying the 2 different pain types.</p><p>BTA has been previously used to treat neuropathic pain.<sup>[<xref rid="R31" ref-type="bibr">31</xref>,<xref rid="R32" ref-type="bibr">32</xref>]</sup> Its pain relief effect might be mediated through the sensory system.<sup>[<xref rid="R27" ref-type="bibr">27</xref>]</sup>The dosage of BTA previously used for treating neuropathic pain was between 2.5 and 7.5&#x0200a;U/cm<sup>2</sup> at each painful surface area with the maximum total dosage from 100 to 200 U.<sup>[<xref rid="R31" ref-type="bibr">31</xref>,<xref rid="R32" ref-type="bibr">32</xref>]</sup> In this study, the painful surface area in patients with SCI was larger than that in patients with other diseases. Therefore, we used the dose of BTA at 200 U at the painful area, and the maximal injection area was &#x0003c;20% of the total body surface.</p><p>Although several clinical studies have reported the positive effect of BTA for neuropathic pain relief, its mechanism is still far from clarity. The previous study found that BTA may reduce the neuropathic pain of SCI by regulating the receptors and ion channels from the reorganization of the nervous system and its functional changes.<sup>[<xref rid="R33" ref-type="bibr">33</xref>]</sup> Some other studies found that neuropeptides played a very pivotal role in the process of the peripheral sensitization in nociception.<sup>[<xref rid="R34" ref-type="bibr">34</xref>,<xref rid="R35" ref-type="bibr">35</xref>]</sup> Therefore, the possible mechanisms of BTA injection for treating neuropathic pain in patients with SCI may be by preventing neuropeptides in the periphery and the spinal cord. In addition, BTA might induce neuropathic pain relief by decreasing calcium-mediated neurotransmitter release.<sup>[<xref rid="R36" ref-type="bibr">36</xref>]</sup></p><p>In this study, our results demonstrated that 200 U BTA injection at each painful area is safe and effective in reducing the VAS and SF-MPQ scores in patients with SCI with neuropathic pain. BTA also significantly improved the WHOQOL-BREF score than placebo.</p><p>This study has several limitations. First, this study was conducted only at the Hongqi Hospital of Mudanjiang medical school, and all the participants were Han Chinese, which might have influenced the generalizability of our findings to patients in other hospitals and other ethnicities. Second, pain relief was evaluated using the VAS, which is a relatively subjective tool and may be affected by multiple unknown factors. Finally, it was impossible for patients to interrupt their standard medication regimens; hence, most patients continued to take their daily medications. Although the baseline medication was similar between the 2 treatment groups, the observed effect might have been the result of the synergistic effect of BTA and medication and not BTA alone.</p><p>The results of this study showed that the administration of BTA injections in patients with SCI induced a significant neuropathic pain relief and was safe. Future clinical trials are still needed to further explore its mechanism and optimal administration, such as dose, duration, and onset time.</p></sec></body><back><fn-group><fn fn-type="abbr"><p>Abbreviations: AEs = adverse events, ASIA = American Spinal Injury Association, BTA = botulinum toxin A, ITT = intention-to-treat, SCI = spinal cord injury, SF-MPQ = short-form McGill Pain Questionnaire, VAS = visual analog scale, WHOQOL-BREF = World Health Organization quality of life.</p></fn><fn fn-type="supported-by"><p>This study was partly supported by the Program of Heilongjiang Education Department (12541853), Program for Innovation Research Team in Science and Technology in Heilongjiang Province University, Program for Innovation Research Team in Science and Technology in Heilongjiang Province University (to Z.S.J), and Natural Science Foundation of Heilongjiang (H201377).</p></fn><fn fn-type="COI-statement"><p>The authors have no conflicts of interest to disclose.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawatzky</surname><given-names>B</given-names></name><name><surname>Bishop</surname><given-names>CM</given-names></name><name><surname>Miller</surname><given-names>WC</given-names></name><etal/></person-group>
<article-title>Classification and measurement of pain in the spinal cord-injured population</article-title>. <source>Spinal Cord</source>
<year>2008</year>;<volume>46</volume>:<fpage>2</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="pmid">17968403</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>TS</given-names></name><name><surname>Baron</surname><given-names>R</given-names></name><name><surname>Haanp&#x000e4;&#x000e4;</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>A new definition of neuropathic pain</article-title>. <source>Pain</source>
<year>2011</year>;<volume>152</volume>:<fpage>2204</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">21764514</pub-id></mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>GC</given-names></name><name><surname>Carroll</surname><given-names>D</given-names></name><name><surname>Parry</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Epidemiology and treatment of neuropathic pain: the UK primary care perspective</article-title>. <source>Pain</source>
<year>2006</year>;<volume>122</volume>:<fpage>156</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">16545908</pub-id></mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Qi</surname><given-names>B</given-names></name><name><surname>Ge</surname><given-names>D</given-names></name></person-group>
<article-title>Intrathecal SB366791 prevents spinal ephrinB1/EphB1 signaling activation-induced acute thermal hyperalgesia</article-title>. <source>Eur J Bio Med Res</source>
<year>2015</year>;<volume>1</volume>:<fpage>36</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>KT</given-names></name><name><surname>Lee</surname><given-names>RP</given-names></name><name><surname>Yu</surname><given-names>TC</given-names></name><etal/></person-group>
<article-title>Surgical outcome of spinal neurilemmoma: two case reports</article-title>. <source>Medicine (Baltimore)</source>
<year>2015</year>;<volume>94</volume>:<fpage>e490</fpage>.<pub-id pub-id-type="pmid">25654395</pub-id></mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Lou</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name></person-group>
<article-title>Migration of titanium cable into spinal cord and spontaneous C2 and C3 fusion: case report of possible causes of fatigue failure after posterior atlantoaxial fixation</article-title>. <source>Medicine (Baltimore)</source>
<year>2016</year>;<volume>95</volume>:<fpage>e5744</fpage>.<pub-id pub-id-type="pmid">28033285</pub-id></mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kehlet</surname><given-names>H</given-names></name><name><surname>Jensen</surname><given-names>TS</given-names></name><name><surname>Woolf</surname><given-names>CJ</given-names></name></person-group>
<article-title>Persistent postsurgical pain: risk factors and prevention</article-title>. <source>Lancet</source>
<year>2006</year>;<volume>367</volume>:<fpage>1618</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">16698416</pub-id></mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddall</surname><given-names>PJ</given-names></name><name><surname>McClelland</surname><given-names>JM</given-names></name><name><surname>Rutkowski</surname><given-names>SB</given-names></name><etal/></person-group>
<article-title>A longitudinal study of the prevalence and characteristics of pain in the first 5 years following spinal cord injury</article-title>. <source>Pain</source>
<year>2003</year>;<volume>103</volume>:<fpage>249</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="pmid">12791431</pub-id></mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ge</surname><given-names>D</given-names></name><name><surname>Qi</surname><given-names>B</given-names></name><name><surname>Tang</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Intraoperative dexmedetomidine promotes postoperative analgesia in patients after spinal surgery</article-title>. <source>Eur J Bio Med Res</source>
<year>2015</year>;<volume>1</volume>:<fpage>2</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Posterior arthrodesis of C1-C3 for the stabilization of multiple unstable upper cervical fractures with spinal cord compromise: a case report and literature review</article-title>. <source>Medicine (Baltimore)</source>
<year>2017</year>;<volume>96</volume>:<fpage>e5841</fpage>.<pub-id pub-id-type="pmid">28072744</pub-id></mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>WK</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Tao</surname><given-names>SQ</given-names></name><etal/></person-group>
<article-title>The application of hydrogels to spinal cord injury</article-title>. <source>Eur J Bio Med Res</source>
<year>2016</year>;<volume>2</volume>:<fpage>1</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>J</given-names></name><name><surname>Cardenas</surname><given-names>D</given-names></name><name><surname>Warms</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Chronic pain associated with spinal cord injury: a community survey</article-title>. <source>Arch Phys Med Rehabil</source>
<year>2001</year>;<volume>82</volume>:<fpage>501</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">11295011</pub-id></mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attal</surname><given-names>N</given-names></name><name><surname>Haanpaa</surname><given-names>M</given-names></name><name><surname>Hansson</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>EFNS guidelines on pharmacological treatment of neuropathic pain</article-title>. <source>Eur J Neurol</source>
<year>2006</year>;<volume>13</volume>:<fpage>1153</fpage>&#x02013;<lpage>69</lpage>.<pub-id pub-id-type="pmid">17038030</pub-id></mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rintala</surname><given-names>DH</given-names></name><name><surname>Holmes</surname><given-names>SA</given-names></name><name><surname>Feiss</surname><given-names>RN</given-names></name><etal/></person-group>
<article-title>Prevalence and characteristics of chronic pain in veterans with spinal cord injury</article-title>. <source>J Rehabil Res Dev</source>
<year>2005</year>;<volume>42</volume>:<fpage>573</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">16586183</pub-id></mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>RF</given-names></name><name><surname>Asghari</surname><given-names>A</given-names></name><name><surname>Egorov</surname><given-names>DD</given-names></name><etal/></person-group>
<article-title>Impact of spinal cord injury on self-perceived pre- and postmorbid cognitive, emotional and physical functioning</article-title>. <source>Spinal Cord</source>
<year>2007</year>;<volume>45</volume>:<fpage>429</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="pmid">17228355</pub-id></mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finnerup</surname><given-names>NB</given-names></name><name><surname>Otto</surname><given-names>M</given-names></name><name><surname>McQuay</surname><given-names>HJ</given-names></name><etal/></person-group>
<article-title>Algorithm for neuropathic pain treatment: an evidence based proposal</article-title>. <source>Pain</source>
<year>2005</year>;<volume>118</volume>:<fpage>289</fpage>&#x02013;<lpage>305</lpage>.<pub-id pub-id-type="pmid">16213659</pub-id></mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hempenstall</surname><given-names>K</given-names></name><name><surname>Nurmikko</surname><given-names>TJ</given-names></name><name><surname>Johnson</surname><given-names>RW</given-names></name><etal/></person-group>
<article-title>Analgesic therapy in postherpetic neuralgia: a quantitative systematic review</article-title>. <source>PLoS Med</source>
<year>2005</year>;<volume>2</volume>:<fpage>164</fpage>.</mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>AB</given-names></name><name><surname>Molenaers</surname><given-names>G</given-names></name><name><surname>Colosimo</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Clinical value of botulinum toxin in neurological indications</article-title>. <source>Eur J Neurol</source>
<year>2006</year>;<volume>13</volume><issue>(suppl 4)</issue>:<fpage>20</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">17112346</pub-id></mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brashear</surname><given-names>A</given-names></name><name><surname>Gordon</surname><given-names>MF</given-names></name><name><surname>Elovic</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Botox post-stroke spasticity study group. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke</article-title>. <source>N Engl J Med</source>
<year>2002</year>;<volume>347</volume>:<fpage>395</fpage>&#x02013;<lpage>400</lpage>.<pub-id pub-id-type="pmid">12167681</pub-id></mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranoux</surname><given-names>D</given-names></name><name><surname>Attal</surname><given-names>N</given-names></name><name><surname>Morain</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain</article-title>. <source>Ann Neurol</source>
<year>2008</year>;<volume>64</volume>:<fpage>274</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">18546285</pub-id></mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>RY</given-names></name><name><surname>Sheu</surname><given-names>JJ</given-names></name><name><surname>Yu</surname><given-names>JM</given-names></name><etal/></person-group>
<article-title>Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial</article-title>. <source>Neurology</source>
<year>2009</year>;<volume>72</volume>:<fpage>1473</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">19246421</pub-id></mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>L</given-names></name><name><surname>Mackey</surname><given-names>S</given-names></name><name><surname>Hui</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Subcutaneous injection of botulinum toxin A is beneficial in postherpetic neuralgia</article-title>. <source>Pain Med</source>
<year>2010</year>;<volume>11</volume>:<fpage>1827</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">21134121</pub-id></mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>M</given-names></name><name><surname>Khanijou</surname><given-names>S</given-names></name><name><surname>Rubino</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Subcutaneous administration of botulinum toxin A reduces formalin-induced pain</article-title>. <source>Pain</source>
<year>2004</year>;<volume>107</volume>:<fpage>125</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">14715398</pub-id></mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luvisetto</surname><given-names>S</given-names></name><name><surname>Marinelli</surname><given-names>S</given-names></name><name><surname>Lucchetti</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Botulinum neurotoxins and formalin-induced pain: central vs peripheral effects in mice</article-title>. <source>Brain Res</source>
<year>2006</year>;<volume>1082</volume>:<fpage>124</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">16524562</pub-id></mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aoki</surname><given-names>KR</given-names></name></person-group>
<article-title>Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A</article-title>. <source>Neurotoxicology</source>
<year>2005</year>;<volume>26</volume>:<fpage>785</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="pmid">16002144</pub-id></mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bach-Rojecky</surname><given-names>L</given-names></name><name><surname>Lackovic</surname><given-names>Z</given-names></name></person-group>
<article-title>Central origin of the antinociceptive action of botulinum toxin type A</article-title>. <source>Parmacol Biochem Behav</source>
<year>2009</year>;<volume>94</volume>:<fpage>234</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matak</surname><given-names>I</given-names></name><name><surname>Lackovic</surname><given-names>Z</given-names></name></person-group>
<article-title>Botulinum toxin A, brain and pain</article-title>. <source>Prog Neurobiol</source>
<year>2014</year>;<fpage>119</fpage>&#x02013;<lpage>20</lpage>. <comment>39-59</comment>.</mixed-citation></ref><ref id="R28"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Min</surname><given-names>SK</given-names></name><name><surname>Kim</surname><given-names>KI</given-names></name><name><surname>Lee</surname><given-names>CI</given-names></name><etal/></person-group>
<article-title>Development of the Korean version of WHO Quality of Life scale and WHOQOL-BREF</article-title>. <source>Qual Life Res</source>
<year>2002</year>;<volume>11</volume>:<fpage>593</fpage>&#x02013;<lpage>600</lpage>.<pub-id pub-id-type="pmid">12206580</pub-id></mixed-citation></ref><ref id="R29"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Widerstr&#x000f6;m-Noga</surname><given-names>E</given-names></name><name><surname>Biering-S&#x000f8;rensen</surname><given-names>F</given-names></name><name><surname>Bryce</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>The international spinal cord injury pain basic data set</article-title>. <source>Spinal Cord</source>
<year>2008</year>;<volume>46</volume>:<fpage>818</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">18521092</pub-id></mixed-citation></ref><ref id="R30"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddall</surname><given-names>PJ</given-names></name><name><surname>Yezierski</surname><given-names>RP</given-names></name><name><surname>Loeser</surname><given-names>JD</given-names></name></person-group>
<article-title>Pain following spinal cord injury: clinical features, prevalence, and taxonomy</article-title>. <source>Int Assoc Study Pain Newlett</source>
<year>2000</year>;<volume>3</volume>:<fpage>3</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="R31"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apalla</surname><given-names>Z</given-names></name><name><surname>Sotiriou</surname><given-names>E</given-names></name><name><surname>Lallas</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single-dose, placebo-controlled trial</article-title>. <source>Clin J Pain</source>
<year>2013</year>;<volume>29</volume>:<fpage>857</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">23370074</pub-id></mixed-citation></ref><ref id="R32"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fabregat</surname><given-names>G</given-names></name><name><surname>De Andres</surname><given-names>J</given-names></name><name><surname>Villanueva-Perez</surname><given-names>VL</given-names></name><etal/></person-group>
<article-title>Subcutaneous and perineural botulinum toxin type A for neuropathic pain: a descriptive review</article-title>. <source>Clin J Pain</source>
<year>2013</year>;<volume>29</volume>:<fpage>1006</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">23370086</pub-id></mixed-citation></ref><ref id="R33"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finnerup</surname><given-names>NB</given-names></name><name><surname>Baastrup</surname><given-names>C</given-names></name></person-group>
<article-title>Spinal cord injury pain: mechanisms and management</article-title>. <source>Curr Pain Headache Rep</source>
<year>2012</year>;<volume>16</volume>:<fpage>207</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="pmid">22392531</pub-id></mixed-citation></ref><ref id="R34"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leem</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>HK</given-names></name><name><surname>Hulsebosch</surname><given-names>CE</given-names></name><etal/></person-group>
<article-title>Ionotropic glutamate receptors contribute to maintained neuronal hyperexcitability following spinal cord injury in rats</article-title>. <source>Exp Neurol</source>
<year>2010</year>;<volume>224</volume>:<fpage>321</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">20211179</pub-id></mixed-citation></ref><ref id="R35"><label>[35]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchand</surname><given-names>F</given-names></name><name><surname>Perretti</surname><given-names>M</given-names></name><name><surname>McMahon</surname><given-names>SB</given-names></name></person-group>
<article-title>Role of the immune system in chronic pain</article-title>. <source>Nat Rev Neurosci</source>
<year>2005</year>;<volume>6</volume>:<fpage>521</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">15995723</pub-id></mixed-citation></ref><ref id="R36"><label>[36]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pozzi</surname><given-names>D</given-names></name><name><surname>Condliffe</surname><given-names>S</given-names></name><name><surname>Bozzi</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Activity-dependent phosphorylation of Ser187 is required for SNAP-25-negative modulation of neuronal voltage-gated calcium channels</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2008</year>;<volume>105</volume>:<fpage>323</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">18162553</pub-id></mixed-citation></ref></ref-list></back></article>